Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

F-Star Therapeutics Inc (NQ: FSTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about F-Star Therapeutics Inc

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Nuvalent (NASDAQ:NUVL) stock increased by 15.9% to $25.5 during Friday's pre-market session. The company's market cap stands at $1.2 billion. 
Via Benzinga
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per... 
Via Benzinga
F-star Therapeutics Shares Are Rallying Today - Read Why
Via Benzinga
Recap: F-star Therapeutics Q1 Earnings
F-star Therapeutics (NASDAQ:FSTX) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
F-STAR THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022
  
Via Benzinga
FSTX STOCK ALERT: Halper Sadeh LLP Is Investigating Whether the Sale of F-star Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Week In Review: InvoX, A Sino Biopharma Company, To Pay $161 Million To Acquire F-Star
InvoX Pharma, a Sino Biopharma subsidiary, will pay $161 million to acquire F-Star, a clinical stage company developing bispecific drugs for immunotherapies. Meanwhile, Reistone Biopharma completed a... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
Upgrades 
Via Benzinga
F-STAR THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX
From Kahn Swick & Foti, LLC
Via Business Wire
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
Nasdaq Jumps Over 100 Points; Applied Therapeutics Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Market Rebound Resumes, Dow Up Triple Digits
Stocks are comfortably higher midday, as the market resumes its rally. 
Via Talk Markets
Dow Jones Turns Lower; F-star Therapeutics Shares Spike Higher
U.S. stocks pared gains midway through trading, with the Dow Jones dropping 100 points on Thursday. 
Via Benzinga
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering. 
Via Benzinga
FSTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of F-star Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
U.S. Markets Open Higher; Jobless Claims Drop To 229,000
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 200 points on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning! It's time to start off another busy day of trading with a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2022
Upgrades Loop Capital upgraded the previous rating for Aspen Technology Inc (NASDAQ:AZPN) from Hold to Buy. In the second quarter, Aspen Technology showed an EPS of $1.20,... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 31.0% to $1.31 during Thursday's pre-market session. The company's market cap stands at $36.7 million.... 
Via Benzinga
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Sensus Healthcare (NASDAQ:SRTS) shares moved upwards by 18.6% to $8.1 during Wednesday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Peering Into F-star Therapeutics Recent Short Interest
F-star Therapeutics Inc. - Common Stock's (NASDAQ:FSTX) short percent of float has fallen 90.16% since last its last report. The company recently reported that it has 108.00... 
Via Benzinga
F-star Shares Rise On Bispecific Antibody Therapeutics Pact With Janssen
F-star Therapeutics Ltd (NASDAQ: FSTX) has entered into a license and collaboration agreement with Janssen Biotech Inc, a unit of Johnson & Johnson... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.